Date of report 30 May 2024

Reported case interaction between **Bictegravir** and **Cytisine**

Drugs suspected to be involved in the DDI

Bictegravir

Daily Dose
50 (mg)

Dose adjustment performed
No

Administration Route
Oral

Start date
Jan. 1, 2018

End date
Ongoing

Cytisine

Daily Dose
Unknown

Dose adjustment performed
No

Administration Route
Oral

Start date
March 1, 2024

End date
March 26, 2024

Complete list of drugs taken by the patient

Antiretroviral treatment

Bictegravir/Emtricitabine/Tenofovir-AF

Complete list of all comedications taken by the patient, included that involved in the DDI

Cytisine

Clinical case description

Gender

Male

Age

58

eGFR (mL/min)

>60

Liver function impairment

No

Description

A 58-year-old male with an HIV infection known since 2018, had an undetectable viral load while on stable treatment with BIC/F/TAF. In March 2024, the patient started taking cytisine for smoking cessation, initially with six 1.5 mg tablets per day for five days before stopping smoking, and gradually reducing the dose to two tablets per day over 25 days, as recommended in the prescribing information. No adverse events occurred while on treatment with cytisine. The HIV plasma viral load remains <20 copies/mL.

Clinical Outcome

No unwanted outcome

Editorial Comment

Cytisine is becoming widely used for smoking cessation. It is primarily excreted renally as an unchanged drug. There are no reports of CYP or transporter involvement on cytisine pharmacokinetics, making clinically significant interactions with antiretroviral treatment unlikely.

University of Liverpool Recommendation

- No clinically significant interaction expected

For more information click here

Personal information from the specialist

Name
José

Surname
Moltó

Institution
Fundació Lluita contra les Infeccions

Country
ES